Hess B, Keusch G, Flückiger J, Binswanger U
Schweiz Med Wochenschr. 1984 Jan 7;114(1):16-9.
The pharmacokinetics of phenytoin are studied in 2 patients on CAPD treatment. Free and protein bound phenytoin are lost in the dialysate. The peritoneal clearance of phenytoin varies from 1.6 to 2.4 ml/min. The peritoneal mass transfer varies from 0.022 to 0.059 mumol/min, depending on the phenytoin dose given. The dialysate concentrations of phenytoin reach 40% of the serum levels. Peritoneal losses of phenytoin may be 5% of the daily intake. The clinical significance of serum level measurements in monitoring of phenytoin therapy is discussed. Beside clinical symptoms, the serum free phenytoin level is of most importance. In uremic patients the albumin-bound fraction of phenytoin is reduced.
在2例接受持续性非卧床腹膜透析(CAPD)治疗的患者中研究了苯妥英的药代动力学。游离型和蛋白结合型苯妥英均会在透析液中丢失。苯妥英的腹膜清除率在1.6至2.4 ml/分钟之间变化。腹膜质量转运在0.022至0.059 μmol/分钟之间变化,这取决于所给予的苯妥英剂量。苯妥英的透析液浓度达到血清水平的40%。苯妥英的腹膜丢失量可能占每日摄入量的5%。讨论了血清水平测量在监测苯妥英治疗中的临床意义。除了临床症状外,血清游离苯妥英水平最为重要。在尿毒症患者中,苯妥英与白蛋白结合的部分减少。